JGC
IMMU

J. Goldman & Co’s Immunomedics Inc IMMU Stock Holding History

J. Goldman & Co’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-123,500
Closed -$1.76M – 358
2018
Q4 		$1.76M Buy
+123,500
New +$2.45M 0.14% 150
2017
Q4 		– Sell
-52,000
Closed -$727K – 477
2017
Q3 		$727K Buy
+52,000
New +$518K 0.04% 256

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

J. Goldman & Co's IMMU Position: Q3 2020 in Review

J. Goldman & Co sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 90,276 shares — an estimated $3.2M sold.

J. Goldman & Co first reported a position in IMMU in Q3 2016 and held it in 4 quarters. The position peaked at $5.51M in Q3 2016. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.

  • J. Goldman & Co reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
  • J. Goldman & Co sold 90,276 Immunomedics Inc shares in Q3 2020, an estimated $3.2M.
  • J. Goldman & Co first reported a position in Immunomedics Inc in Q3 2016 and held it in 4 quarters.
  • J. Goldman & Co's Immunomedics Inc position peaked at $5.51M in Q3 2016.
  • 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.

Based on J. Goldman & Co's 13F filing for Q3 2020, filed 16 Nov 2020.